Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B | Zendy

John J.P. Kastelein | Zendy; Mark K. Wedel | Zendy; Brenda F. Baker | Zendy; John Q. Su | Zendy; JoAnn D. Bradley | Zendy; Rosie Z. Yu | Zendy; Emil Chuang | Zendy; Mark J. Graham | Zendy; Rosanne M. Crooke | Zendy

Open Access

Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

Author(s) -

John J.P. Kastelein,

Mark K. Wedel,

Brenda F. Baker,

John Q. Su,

JoAnn D. Bradley,

Rosie Z. Yu,

Emil Chuang,

Mark J. Graham,

Rosanne M. Crooke

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.606442

Subject(s) - apolipoprotein b , medicine , pharmacology , dyslipidemia , endocrinology , placebo , lipoprotein , adverse effect , cholesterol , diabetes mellitus , pathology , alternative medicine

Apolipoprotein B (apoB) is an important structural component of low-density lipoprotein cholesterol (LDL-C) and plays a key role in LDL-C transport and removal. Reduction in apoB synthesis is expected to reduce circulating LDL-C, a proven risk factor of cardiovascular disease. In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research